Rapid Production of Human Neuronal Cultures with Single Cell Resolution

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a method for rapidly converting human neural stem cells or neural progenitor cells into induced neuronal cells with single-cell resolution. The core invention involves using a specially designed transcription factor (TF) that binds to a specific DNA sequence (DR0 response element) in the genome and includes a strong activation region (transactivation domain). This method notably accelerates neuronal differentiation—enabling the formation of homogeneous neuron cultures within 48 hours. The resultant cultures are well-suited for applications like high-content imaging, drug screening, disease modeling, and potentially cell therapies for neurological diseases.

Use CasesContent extracted from patent full text and abstract with AI.

• Rapid generation of human neurons for high-throughput drug screening platforms, particularly in neurological disease research.
• Production of uniform neuronal cultures for disease modeling (e.g., Alzheimer’s, Parkinson’s, autism spectrum disorders, etc.).
• Basic biomedical research needing large quantities of human neurons with minimal variability.
• Neuronal cell therapy, including transplantation into patients suffering from neurological damage, neuronal loss, or neurodegenerative diseases.
• Toxicology and safety testing of candidate pharmaceuticals using human neurons in vitro.
• Genetic studies on neuronal differentiation and development.

BenefitsContent extracted from patent full text and abstract with AI.

• Very rapid conversion of neural stem/progenitor cells into neurons (within 24-48 hours), much faster than conventional protocols.
• Resulting neuron cultures are homogeneous, have controlled density, and minimal clustering, which facilitates single-cell analysis and high-content imaging.
• Eliminates the need for anti-mitotic drugs or labor-intensive replating steps required in existing differentiation methods.
• Can generate large amounts of neurons from cryopreserved stem cell lines—helpful for scalability and reproducibility in research and industry.
• Lower cost and improved reproducibility versus existing technologies.
• Versatile—enables not just drug discovery and disease modeling, but also potentially clinical applications in cell-replacement therapies.
• The process is well-suited for automated or high-throughput workflows, enhancing its practicality in drug development pipelines.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention provides a method of converting one or more neural cells (NCs) into one or more induced neuronal cells, comprising (a) providing NCs; and (b) contacting the NCs with a transcription factor (TF) or expressing the TF within the NCs, wherein the TF comprises a DNA binding moiety and a transactivation domain (TAD), wherein the DNA binding moiety specifically binds to a direct repeat with zero spacing (DR0) response element; thereby producing induced neuronal cells. The invention further provides methods of converting one or more neural cells (NCs) into one or more induced neuronal cells by inhibiting the expression of GCNF in the NCs or expressing a GCNF target gene in the NCs or contacting the NCs with the gene product of a GCNF target gene. The present invention also provides a TF comprising a DNA binding moiety specifically binding to a direct repeat with zero spacing (DR0) response element and a TAD, a nucleic acid comprising said TF, a vector comprising said nucleic acid and a cell comprising said TF. In addition, the invention provides said cell for use in a method of treatment or prevention of a neurological condition as well as the use of said cell in a method of drug screening or as a disease model.